ICICI Securities research report on Dr Lal Pathlabs
Dr Lal PathLabs’ (Dr Lal) Q4FY25 results were slightly better than our expectation. Outperformance was driven by higher sample volumes (up 9.5% YoY) and realisation improvement. Revenue per patients surged 6.4% YoY (2.9% QoQ) due to favourable test and geography mix, which drove operating leverage and boosted EBITDA margins by 150bps to 28%. In FY25, the company opened 18 labs in tier -3/4 cities and 15–20 more shall be opened next year.
Outlook
Network expansion, investment in new technologies and lack of price hikes on majority of the portfolio may exert pressure on margins in FY26. Management guides for 11–12% revenue growth and conservative 27% margins for FY26. Dr Lal reported cash balance of INR 12.3bn, which shall be deployed for adding new capabilities, M&A opportunities in south and dividends. Retain HOLD with a target price of INR 2,900.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
